Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study)

A. T. Fung, N. Kumar, S. K. Vance, J. S. Slakter, J. M. Klancnik, R. S. Spaide, K. B. Freund*

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

53 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Pilot study to evaLuate the role of high-dose rAnibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with perSistent/recurrenT macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study)'. Together they form a unique fingerprint.

Medicine & Life Sciences